U.S. COMPANY RESULTS
Only half of U.S. chemical and drug firms tracked by C&EN saw profits grow in 2012
(Monetary figures, except per-share amounts, are in millions of dollars)
|
YEAR |
NET SALES ($) |
EARNINGS ($) |
PROFIT MARGIN (%) |
TOTAL ASSETS ($) |
STOCKHOLDERS' EQUITY ($) |
RETURN ON EQUITY (%) |
CAPITAL SPENDING, % OF SALES |
R&D SPENDING, % OF SALES |
EARNINGS PER SHARE ($) |
DIVIDEND, $ PER SHARE |
DIVIDEND YIELD, % OF PRICE |
STOCK PRICE RANGE, PER SHARE ($) |
PRICE/EARNINGS RATIO |
| HIGH |
LOW |
a Fiscal year ends on Sept. 30. b Acquired International Specialty Products in 2011. c Formerly Georgia Gulf. d Acquired Terra Industries in 2010. e Acquired Rohm and Haas in 2009. f Acquired Danisco in 2011. g Acquired Solutia in 2012. h Fiscal year ends on Dec. 1. i Acquired Schering-Plough in 2009. j Acquired Wyeth in 2009 and Icagen in October 2011. def = deficit. ne = nonexistent.
Click on the arrows to sort table.
If you are having trouble viewing this table, click here for a PDF.
<< Back to Finance: No Growth, No Problem
